NewCardio Signs MSA with United States Based CRO for QTinno
NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, announced that a U.S.-based CRO that provides early phase and specialty clinical drug development services to the pharmaceutical industry, has signed an MSA, licensing NewCardio's QTinno™ software solution in order to deliver fully automated cardiac safety analysis in early phase QT studies.
In addition, the CRO has signed a services work order, including standard operating procedures (SOP) and validation kits, as well as professional services, in order to accelerate its readiness for delivering ECG core lab services to its sponsor customers. Revenue from the professional services agreement is expected to be recognized during March 2010 with the implementation scheduled to be complete within the next 4-6 weeks. NewCardio has recognized its first operating revenues as a result of this order.
"One of our target customers is clinical trial service providers, looking to deploy our proven technology to expand services and grow market opportunities. For this CRO, adding to its available scope of services, by utilizing QTinno, accomplished these two important goals," said Vincent Renz, NewCardio President and Chief Operating Officer.
QTinno is a software suite that provides an automated analysis of QT intervals and other ECG-based cardiac safety for the pharmaceutical industry and drug regulators.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
